How Gilead's blood cancer med Zydelig might also address triple-negative breast cancer

Triple-negative breast cancer is hard to treat, because it lacks common markers for drugs to target. Now, instead of going after the tumors directly, a research team led by the University of Sussex has found a target in their surrounding environment and identified Gilead's FDA-approved blood cancer med Zydelig as a possible treatment.